Advancements in pulmonary drug delivery systems have expanded their potential application in other diseases as well including diabetes, lung cancer, and others. The market for pulmonary drug delivery systems is projected to be worth US$28.7 bn by the end of 2019, propagating at a notable CAGR of 4.4% during the forecast period of 2017 to 2019.

Source: Click here